Relyvrio’s Failure Sparks NeuroSense ALS Development Changes

 
• By Derrick Gingery
  
neuron-degeneration
NeuroSense is planning a Phase III study for its ALS candidate PrimeC. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D